Shots:

• Sangamo has an option to access Brammer’s AAV manufacturing facility with 2000-L bioreactor scale used in development of gene therapies. Additionally- Sangamo has rights for Brammer’s viral vector manufacturing facility to utilize it in combination with its California facility to expand its early stage products to late stage
• The focus of the agreement is to develop AVV-based genomic in-vivo & ex-vivo therapies and genome editing candidates including ST-920 for Fabry Disease utilizing Brammer’s manufacturing facilities
• ST-920 is a gene therapy candidate with AAV vector carrying a GLA gene enabling the liver to produce α-Gal A enzyme and will be evaluated in P-I/II for Fabry disease in 2019. In 2020- Sangamo plans to build cGMP manufacturing facilit in Brisbane- California- for P-I/II trials of products

Click here to read full press release/ article | Ref: Sangamo Therapeutics | Image: Twitter